



Designation: **F2914 – 12 F2914 – 12 (Reapproved 2018)**

Standard Guide for Identification of Shelf-life Test Attributes for Endovascular Devices¹

This standard is issued under the fixed designation F2914; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This guide addresses the determination of appropriate device attributes for testing as part of a shelf-life study for endovascular devices. Combination and biodegradable devices (for example drug-devices, biologic devices or drug biologics) may require additional considerations, depending on their nature.

1.2 This guide does not directly provide any test methods for conducting shelf-life testing.

~~1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.~~

1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.4 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

2. Terminology

2.1 Definitions:

2.1.1 *endovascular device*—device used to treat vascular disease from within the vessel.

2.1.2 *product*—final packaged and sterilized device with all included components.

2.1.3 *shelf life*—the amount of real time that a fully packaged (and sterilized, if applicable) product can be expected to remain in storage at specified conditions and maintain its critical performance properties.

3. Significance and Use

3.1 The purpose of this guide is to provide a procedure for determining the appropriate attributes to evaluate in a shelf-life study for an endovascular device.

4. Procedure

4.1 *Shelf-life Establishment Model Introduction*—The decision flow chart (**Fig. 1**) assists study developers in selecting and justifying risk-appropriate test protocols for medical devices to establish shelf life. The decision flowchart is intended to elicit questions and an appropriate rationale for testing or not testing a particular attribute during aging. The risk to the patient as the device ages is one of the primary drivers. It is recommended that all regulatory requirements and guidances be considered during development of the shelf-life establishment test plan. See **Fig. 1**.

4.2 *Question 1: “Could the device attribute change over time?”*:

4.2.1 *Considerations in Evaluating Question 1*—This question must be addressed based on the device design characteristics (and also in relation to the device being packaged, sterilized, shipped and stored).

4.2.1.1 Consider attributes such as the following, for example:

¹ This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.30 on Cardiovascular Standards.

Current edition approved Jan. 15, 2012; Nov. 1, 2018. Published February 2012; November 2018. DOI:10.1520/F2914-12. Originally approved in 2012. Last previous edition approved in 2012 as F2914-12. DOI:10.1520/F2914-12R18.

**Device Aging Shelf
Life Establishment
Study**




FIG. 1 Device Aging Shelf-life Establishment Flow Chart



- (1) *Material Properties/Characterization*—Composition; Mechanical Properties; Corrosion Resistance
- (2) *Dimensional and Functional Properties*—Dimensions; Surface Area; Foreshortening
- (3) *Deliverability and Functionality*—Balloon Fatigue; Balloon Rated Burst; Bond Tensile Strength

4.2.1.2 Various sources may provide sufficient evidence to confirm that some specific attributes do not change over time for the application or that the change is not a risk to the patient.

- (1) Scientific literature.
- (2) Appropriate vendor publication.
- (3) In-house research.
- (4) Assessment of clinically accepted device.

4.2.1.3 When using such data to justify why certain attributes may not require shelf-life testing, consider all differences between the subject device and the source of those data to ensure applicability. For example, vendor literature may not represent the actual use of the material by the device manufacturer. Additionally, further processing (for example, sterilization) may change the physical or chemical attribute(s) of the material. Finally consider whether there are interactions (chemical or physical) that may impact your assessment.

4.2.1.4 In order for testing to be applicable, the testing must be conducted on articles that are representative of the final device (that is, utilizing the same sterilization method and dose, dimensions, material, processing conditions, and packaging). If test articles are not identical, provide appropriate justification for applicability of the testing.

4.2.2 *Justification Based upon Scientific Principles*—When one considers whether an attribute should be included in a shelf-life study, the first question is whether the attribute changes over time. There are several device attributes that may be driven by physical parameters of the device that would not change over time and therefore will not require shelf-life testing. The assessment should be conducted using universal scientific/physical principles. In cases where the assessment is based on universal scientific/physical principal, appropriate references should be provided. In cases where justifications may be less obvious, data to support the scientific/physical rationale shall be generated. **Tables 1 and 2** list two groups of device attributes with accompanying scientific rationale.

4.2.3 *Justification Based upon Data*—Scientific principles for some device attributes/requirements are not readily evident. In such cases, one may generate data to support a rationale. It may be advantageous to conduct testing in a manner that allows for the data to be applicable to various size devices. In this case, it is important to translate the device attribute (such as system flexibility) into the underlying size independent scientific parameters (such as Young’s modulus). Testing is then conducted to evaluate the stability of the core scientific parameter. For each device attribute, more than one scientific parameter may be necessary to demonstrate stability over the aging period. (For simplicity of the examples, only one test parameter is illustrated in **Table 3**.) Each device attribute should be evaluated to determine what scientific parameters may be affected by aging and the appropriate testing to mitigate each of those risks should then be conducted. The attributes evaluated must be conducted on samples that are representative of the device; and the stability evaluation must be equal or greater than the anticipated shelf life. Some hypothetical examples are printed in the remainder of this section. **12(2018)**

4.3 *Question 2: “Will the change have an impact on safety or performance?”*—Once it has been determined that a device attribute is likely to be affected by time and storage conditions, the second question to evaluate is whether the change poses a possible risk to the patient or product performance. Another way of stating the question is: “Will a change in the device attribute, resulting from aging, pose a significant risk to the patient or clinician?” Risk analysis is an appropriate technique used to answer this question. However, since risk analysis methodologies have yet to be standardized, there is no definitive risk level that can be applied universally for all devices and parameters. It will be the responsibility of individual companies to carefully develop the threshold for acceptable risk.

4.3.1 *Basis for Risk Assessment*—The assessment of risk related to a device attribute may be conducted using clinical history (in literature or privately held) or the complaint history of a similar device used in a similar application. Additionally, a scientific/medical argument might provide adequate information to assess the risk.

TABLE 1 Example Attributes Typically Impacted by Aging

| Device Attribute | Scientific Principle |
|---|--|
| Nylon polymer catheter tensile at break | Aging of polymers can result in the breaking of chemical bonds and/or a reduction in polymer chain entanglement. Therefore this dynamic process needs to be assessed after defined shelf-life testing conditions. |
| Balloon rated burst | Aging of polymers can result in the breaking of chemical bonds and/or a reduction in polymer chain entanglement. Therefore this dynamic process needs to be assessed after defined shelf- life conditions. |
| Balloon fatigue | Aging of polymers can result in the breaking of chemical bonds and/or a reduction in polymer chain entanglement. Therefore this dynamic process needs to be assessed after defined shelf-life conditions. |
| Stent securement | Stent securement is driven by interactions between stents and balloon surfaces. Since polymers may relax after time, the engagement of these surfaces may change. Therefore this dynamic process needs to be assessed after defined shelf-life conditions. |